Results 81 to 90 of about 11,226 (207)

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

P28 | ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G-CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE

Haematologica
Daratumumab is increasingly used as a part of the induction therapy in patients with newly diagnosed multiple myeloma (NDMM) and is associated with deeper responses to treatment.
B. Skopec, L. Cemazar, M. Skerget
doaj   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma

, 2013
CD38 is a type II transmembrane glycoprotein that is highly expressed in hematological malignancies, including multiple myeloma (MM). Therefore, CD38 is a promising target for antibody immunotherapy.
Nahi, H,, A. Cakana, Nahi, H., J. Laubach, Laubach, J, Gimsing, P, T. Plesner, Cakana, A, Laubach, J., Lisby, S, P. Gimsing, Palumbo, A, Lokhorst, H., Plesner, T, Plesner, T., Palumbo, A., Lokhorst, H, Cakana, A., H. Nahi, Richardson, P, Brun, N. Constantin, N.C. Brun, Lisby, S., Brun, NC, Richardson, P., S. Lisby, A. Palumbo, Gimsing, P., P. Richardson, H. Lokhorst   +29 more
core   +1 more source

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab

Haematologica
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM).
Guido Lancman, Dahniel Sastow, Minira Aslanova, Erin Moshier, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Ajai Chari   +13 more
doaj   +1 more source

Circadian Deregulation in Multiple Myeloma: BMAL1/CLOCK Expression Patterns and Diagnostic Performance

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Circadian clock disruption has emerged as a relevant axis in cancer; however, the expression patterns and diagnostic relevance of BMAL1 and CLOCK in multiple myeloma (MM) remain insufficiently defined. Methods BMAL1 and CLOCK mRNA expression was quantified by RT‐qPCR in bone marrow samples from 46 newly diagnosed MM patients and 13 ...
Hamide Albayrak, Mustafa Ertan Ay, Anıl Tombak, Kenan Çevik, Özlem İzci Ay, Tuba Kabasakal, Mehmet Emin Erdal   +6 more
wiley   +1 more source

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

, 2013
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients
Gopalakrishnan S, Tan D
core  

B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE

Haematologica
Introduction. Patients with high-risk smoldering multiple myeloma (SMM) may benefit from early treatment. With SMM risk stratification advancement, post hoc analysis of the AQUILA study using IMWG 2020 (“20/2/20”) and other risk models was conducted to ...
F. Schjesvold, P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M-D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringhen, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, Ph. Moreau, M-V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, S.V. Rajkumar   +38 more
doaj   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting, Kangjie Reuel Chua, Li‐Chuen Wong, Gloria Fong   +3 more
wiley   +1 more source